Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$7.5 million.

  • Maxcyte's Cash from Operations fell 6984.74% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.5 million, marking a year-over-year decrease of 11024.03%. This contributed to the annual value of -$27.6 million for FY2024, which is 2731.72% down from last year.
  • As of Q3 2025, Maxcyte's Cash from Operations stood at -$7.5 million, which was down 6984.74% from -$9.9 million recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Cash from Operations peaked at $981000.0 during Q4 2023, and registered a low of -$14.4 million during Q1 2025.
  • For the 5-year period, Maxcyte's Cash from Operations averaged around -$5.6 million, with its median value being -$4.8 million (2024).
  • In the last 5 years, Maxcyte's Cash from Operations skyrocketed by 12094.01% in 2022 and then crashed by 120004.35% in 2023.
  • Over the past 5 years, Maxcyte's Cash from Operations (Quarter) stood at -$960250.0 in 2021, then plummeted by 533.83% to -$6.1 million in 2022, then surged by 116.12% to $981000.0 in 2023, then plummeted by 897.25% to -$7.8 million in 2024, then grew by 4.64% to -$7.5 million in 2025.
  • Its Cash from Operations stands at -$7.5 million for Q3 2025, versus -$9.9 million for Q2 2025 and -$14.4 million for Q1 2025.